RT Journal Article
SR Electronic
T1 Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1065
OP 1071
DO 10.21873/anticanres.15568
VO 42
IS 2
A1 TAKAFUMI SHIMADA
A1 KOUJI IZUMI
A1 HIROSHI KANO
A1 SUGURU KADOMOTO
A1 TOMOYUKI MAKINO
A1 RENATO NAITO
A1 HIROAKI IWAMOTO
A1 HIROSHI YAEGASHI
A1 YOSHIFUMI KADONO
A1 ATSUSHI MIZOKAMI
YR 2022
UL http://ar.iiarjournals.org/content/42/2/1065.abstract
AB Background/Aim: Ra-223 is a therapeutic agent for bone metastatic castration-resistant prostate cancer (mCRPC). We examined the efficacy of a treatment method using Ra-223 together with ethinylestradiol (EE). Patients and Methods: Patients who received Ra-223 three or more times were included and two groups (with or without EE) were compared retrospectively. Results: Eighteen patients were treated with Ra-223 and EE concomitantly (EstRadium therapy) and 13 patients were treated with Ra-223 alone or Ra-223 and agents other than EE (non-EstRadium therapy). The number of patients with decreased serum prostate-specific antigen level was significantly higher in the EstRadium therapy group than in the non-EstRadium therapy group (p=0.029). Conclusion: The combination of Ra-223 and EE, compared to Ra-223 alone, is an effective treatment option for bone mCRPC patients, in terms of PSA response.